CERO THERAPEUTICS HOLDINGS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.15 USD | -0.86% |
|
-11.54% | -89.55% |
| 02/04 | CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 11/03 | Top Premarket Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Companyâs proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the bodyâs full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
| 1st Jan change | Capi. | |
|---|---|---|
| -89.55% | 17.08M | |
| +4.15% | 111B | |
| +11.50% | 105B | |
| -12.53% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.29% | 16.96B | |
| +2.50% | 13.7B | |
| +36.48% | 12.45B |
- Stock Market
- Equities
- CERO Stock
- News CERo Therapeutics Holdings, Inc.
- Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics